Top 35 Startups that help to cure COVID-19 in USA
Apr 10, 2026
|
Like
15
1
Funding: $1.2B
Vir Biotechnology develops immunotherapeutics for the treatment and prevention of infectious diseases, including Flu and Covid19. Its next-generation antibody platform and PRO-XTEN protease-release masking technology are designed to treat infectious diseases and cancer, respectively. The company uses the dAIsY (Data Structure and Antibody AI) platform to design and optimize drug candidates, modulating interactions with the immune system and improving key characteristics that help us create more effective drugs faster. Vir is advancing several candidates for the treatment of hepatitis delta, solid tumors and HIV.
Vir Biotechnology develops immunotherapeutics for the treatment and prevention of infectious diseases, including Flu and Covid19. Its next-generation antibody platform and PRO-XTEN protease-release masking technology are designed to treat infectious diseases and cancer, respectively. The company uses the dAIsY (Data Structure and Antibody AI) platform to design and optimize drug candidates, modulating interactions with the immune system and improving key characteristics that help us create more effective drugs faster. Vir is advancing several candidates for the treatment of hepatitis delta, solid tumors and HIV.
2
Funding: $3.9B
Moderna is a pioneer in developing a new class of drugs based on messenger RNA (mRNA). This new drug platform is based on the discovery that in-vitro engeneered and injected mRNA can direct the body's cellular machinery to produce virtually any protein of interest, from native proteins to antibodies and other entirely new protein constructs with therapeutic activity both inside and outside cells. In other words, mRNA can guide the body to produce its own drugs. Moderna used mRNA to create the first COVID-19 vaccine and is now applying this technology to create vaccines for infectious diseases (influenza, RSV, HSV, etc.), immuno-oncology (melanoma, lung cancer, liver cancer, etc.), rare diseases and autoimmune diseases.
Moderna is a pioneer in developing a new class of drugs based on messenger RNA (mRNA). This new drug platform is based on the discovery that in-vitro engeneered and injected mRNA can direct the body's cellular machinery to produce virtually any protein of interest, from native proteins to antibodies and other entirely new protein constructs with therapeutic activity both inside and outside cells. In other words, mRNA can guide the body to produce its own drugs. Moderna used mRNA to create the first COVID-19 vaccine and is now applying this technology to create vaccines for infectious diseases (influenza, RSV, HSV, etc.), immuno-oncology (melanoma, lung cancer, liver cancer, etc.), rare diseases and autoimmune diseases.
3
Funding: $1.4B
ImmunityBio is a privately held immunotherapy company with one of the broadest portfolios of biological molecules spanning albumin-linked chemotherapeutic, peptides, fusion proteins, cytokine, monoclonal antibodies, adenovirus and yeast vaccine therapies.
ImmunityBio is a privately held immunotherapy company with one of the broadest portfolios of biological molecules spanning albumin-linked chemotherapeutic, peptides, fusion proteins, cytokine, monoclonal antibodies, adenovirus and yeast vaccine therapies.
4
Funding: $622.5M
Carbon Health is a developer of a mobile-based healthcare network used to offer simple, convenient, and accessible healthcare.
Carbon Health is a developer of a mobile-based healthcare network used to offer simple, convenient, and accessible healthcare.
5
Funding: $553.5M
Invivyd develops antibodies to transcend the limitations of the human immune system and fight against viral infections.
Invivyd develops antibodies to transcend the limitations of the human immune system and fight against viral infections.
6
Funding: $553.1M
Twist Bioscience is a synthetic DNA production for specialty chemical compounds and drug development.
Twist Bioscience is a synthetic DNA production for specialty chemical compounds and drug development.
7
Funding: $510.6M
GreenLight Biosciences is using RNA to target some of the world’s biggest problems
GreenLight Biosciences is using RNA to target some of the world’s biggest problems
8
Funding: $506.6M
Medable's platform helps to facilitate the clinical trial process. Its mission is to reduce clinical trial timelines by 50%.
Medable's platform helps to facilitate the clinical trial process. Its mission is to reduce clinical trial timelines by 50%.
9
Funding: $497M
Color provides a high-quality, physician-ordered, genetic test at a low cost. We include support for physicians, as well as genetic counseling as part of every purchase. Our goal is to expand physician-supported access to genetic testing for hereditary cancer risk to every person, everywhere.
Color provides a high-quality, physician-ordered, genetic test at a low cost. We include support for physicians, as well as genetic counseling as part of every purchase. Our goal is to expand physician-supported access to genetic testing for hereditary cancer risk to every person, everywhere.
10
Funding: $496M
Invivyd develops antibodies to transcend the limitations of the human immune system and fight against viral infections.
Invivyd develops antibodies to transcend the limitations of the human immune system and fight against viral infections.
11
Funding: $435M
AlloVir, formerly known as ViraCyte, is a leading innovator in allogeneic, off-the-shelf, multi-virus specific T-cell immunotherapies
AlloVir, formerly known as ViraCyte, is a leading innovator in allogeneic, off-the-shelf, multi-virus specific T-cell immunotherapies
12
Funding: $403M
At Helix, we’re dedicated to making DNA learning accessible and actionable for everyone. It’s our mission to empower every person to improve their life through DNA. We believe in a world where everyone benefits from their biological information and is able to help all of humanity lead better lives.
At Helix, we’re dedicated to making DNA learning accessible and actionable for everyone. It’s our mission to empower every person to improve their life through DNA. We believe in a world where everyone benefits from their biological information and is able to help all of humanity lead better lives.
13
Funding: $400M
Celgene spinout that aims is to develop cells from placentas against blood cancers and is founded on the use of stem cells from placentas. The goal is to create therapies across autoimmune and degenerative disease, immuno-oncology, and functional regeneration.
Celgene spinout that aims is to develop cells from placentas against blood cancers and is founded on the use of stem cells from placentas. The goal is to create therapies across autoimmune and degenerative disease, immuno-oncology, and functional regeneration.
14
Funding: $369.5M
Humanigen is a biopharmaceutical company that uses its biologic capabilities and its proprietary platform technology to develop first-in-class human antibody therapeutics. It focuses on preventing the serious and potentially life-threatening side-effects associated with chimeric antigen receptor T-cell (CAR-T) therapy.
Humanigen is a biopharmaceutical company that uses its biologic capabilities and its proprietary platform technology to develop first-in-class human antibody therapeutics. It focuses on preventing the serious and potentially life-threatening side-effects associated with chimeric antigen receptor T-cell (CAR-T) therapy.
15
Funding: $334.9M
Regeneron Pharmaceuticals specializes in the discovery, development, and commercialization of innovative medicines.
Regeneron Pharmaceuticals specializes in the discovery, development, and commercialization of innovative medicines.
16
Funding: $325M
EverlyWell is a digital health platform that provides at-home health tests and lab results.
EverlyWell is a digital health platform that provides at-home health tests and lab results.
17
Funding: $283.4M
Atea Pharmaceuticals is a biopharmaceutical company which is engaged in the acquisition, discovery and development of novel antiviral therapeutics.
Atea Pharmaceuticals is a biopharmaceutical company which is engaged in the acquisition, discovery and development of novel antiviral therapeutics.
18
Funding: $278.9M
Wearable biosensor technology for wireless hospital and remote patient monitoring
Wearable biosensor technology for wireless hospital and remote patient monitoring
20
Funding: $256M
Truepill provides an API-connected healthcare infrastructure designed to revolutionize the patient experience.
Truepill provides an API-connected healthcare infrastructure designed to revolutionize the patient experience.
21
Funding: $148M
Ashvattha Therapeutics develops therapy thar selectively targets hyper-inflammatory macrophages responsible for excessive cytokine production in severe COVID-19 patients.
Ashvattha Therapeutics develops therapy thar selectively targets hyper-inflammatory macrophages responsible for excessive cytokine production in severe COVID-19 patients.
22
Funding: $139.5M
Eureka Therapeutics is a biotechnology company focusing on immunotherapies for the treatment of cancer.
Eureka Therapeutics is a biotechnology company focusing on immunotherapies for the treatment of cancer.
23
Funding: $119.4M
Ready Responders comprises of multi-disciplinary leading professionals associated with the leading organizations in this arena.
Ready Responders comprises of multi-disciplinary leading professionals associated with the leading organizations in this arena.
24
Funding: $118M
Zoe is leading the world’s largest ongoing nutritional research project in collaboration with scientists from universities including Harvard, King's College London, Massachusetts General Hospital, Oxford and Stanford.
Zoe is leading the world’s largest ongoing nutritional research project in collaboration with scientists from universities including Harvard, King's College London, Massachusetts General Hospital, Oxford and Stanford.
25
Funding: $115.9M
Nurx is offering Truvada as "PrEP," or an HIV preexposure prophylaxis. People looking to get on PrEP can sign up via Nurx's website or smartphone app.
Nurx is offering Truvada as "PrEP," or an HIV preexposure prophylaxis. People looking to get on PrEP can sign up via Nurx's website or smartphone app.
26
Funding: $97.8M
ChromaCode is a molecular diagnostics company focusing on bioinformatics.
ChromaCode is a molecular diagnostics company focusing on bioinformatics.
27
Funding: $84.8M
BioIntelliSense is developing a medical-grade data services platform for remote health monitoring.
BioIntelliSense is developing a medical-grade data services platform for remote health monitoring.
28
Funding: $80.5M
Datavant is a developer of a healthcare data platform dedicated to assisting in protecting, matching, and sharing health data.
Datavant is a developer of a healthcare data platform dedicated to assisting in protecting, matching, and sharing health data.
29
Funding: $54M
Alveo Technologies is changing the world by applying cutting edge advances in sensing, microfluidics, and bioassays to create the next-generation of disease and personal care diagnostic devices.Their innovative products connect and empower consumers, healthcare professionals and treatment providers with the ability to know sooner, act faster, and make better-informed decisions. Advanced diagnostics clear the path to more personalized medicine and better outcomes.
Alveo Technologies is changing the world by applying cutting edge advances in sensing, microfluidics, and bioassays to create the next-generation of disease and personal care diagnostic devices.Their innovative products connect and empower consumers, healthcare professionals and treatment providers with the ability to know sooner, act faster, and make better-informed decisions. Advanced diagnostics clear the path to more personalized medicine and better outcomes.
30
Funding: $11.4M
PureTech Health is developing differentiated medicines for devastating diseases including intractable cancers, lymphatic and GI diseases, CNS disorders and inflammatory and immunological diseases
PureTech Health is developing differentiated medicines for devastating diseases including intractable cancers, lymphatic and GI diseases, CNS disorders and inflammatory and immunological diseases
31
Funding: $42.6M
BioIQ helps people navigate to a broad set of health services at retail locations or in their home.
BioIQ helps people navigate to a broad set of health services at retail locations or in their home.
32
Funding: $38.4M
GigaGen is advancing a pipeline of first-in-class biotherapeutics, including novel oncology antibody drug combinations and the world’s first recombinant polyclonal hyperimmune gammaglobulin. Behind our diverse and growing pipeline is a mission to bring forth a new generation of highly efficacious drugs, driven by an unparalleled understanding of immune dysregulation.
GigaGen is advancing a pipeline of first-in-class biotherapeutics, including novel oncology antibody drug combinations and the world’s first recombinant polyclonal hyperimmune gammaglobulin. Behind our diverse and growing pipeline is a mission to bring forth a new generation of highly efficacious drugs, driven by an unparalleled understanding of immune dysregulation.
33
Funding: $34.3M
Anixa is a publicly-traded biotechnology company focused on harnessing the body's immune system in the fight against cancer. Anixa's therapeutic portfolio includes a cancer vaccine technology focused on the immunization against α-Lactalbumin to prevent triple negative breast cancer (TNBC), as well as a cancer immunotherapy program which uses a novel type of CAR-T, known as chimeric endocrine receptor T-cell (CER-T) technology.
Anixa is a publicly-traded biotechnology company focused on harnessing the body's immune system in the fight against cancer. Anixa's therapeutic portfolio includes a cancer vaccine technology focused on the immunization against α-Lactalbumin to prevent triple negative breast cancer (TNBC), as well as a cancer immunotherapy program which uses a novel type of CAR-T, known as chimeric endocrine receptor T-cell (CER-T) technology.
35
Funding: $27M
care.ai is the first and only AI-powered autonomous monitoring platform for healthcare. care.ai’s platform connects to our purpose-built AI accelerated, edge sensors, to transform ordinary rooms into Self-Aware Rooms.
care.ai is the first and only AI-powered autonomous monitoring platform for healthcare. care.ai’s platform connects to our purpose-built AI accelerated, edge sensors, to transform ordinary rooms into Self-Aware Rooms.
★
See also:
